{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:06:11Z","timestamp":1780628771753,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00843-6","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T17:04:57Z","timestamp":1668618297000},"page":"187-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"13","author":[{"given":"Chen","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-8080","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel T.","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erjia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanshen","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Kerti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"1","key":"843_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2020.06.003","volume":"99","author":"Y Tada","year":"2020","unstructured":"Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Dermatol Sci. 2020;99(1):53\u201361. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.06.003.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"843_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029.","journal-title":"JAMA Dermatol"},{"key":"843_CR3","doi-asserted-by":"publisher","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev.202119;4(4):CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub4. Update in: Cochrane Database Syst Rev. 2022;5:CD011535","DOI":"10.1002\/14651858.CD011535.pub4"},{"issue":"3","key":"843_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jdv.15288","volume":"33","author":"G Deza","year":"2019","unstructured":"Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553\u20139. https:\/\/doi.org\/10.1111\/jdv.15288.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"843_CR5","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1111\/jdv.16568","volume":"34","author":"J Seneschal","year":"2020","unstructured":"Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566\u201373. https:\/\/doi.org\/10.1111\/jdv.16568.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"843_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1346-8138.15146","volume":"47","author":"M Kishimoto","year":"2020","unstructured":"Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33\u201340. https:\/\/doi.org\/10.1111\/1346-8138.15146.","journal-title":"J Dermatol"},{"issue":"2","key":"843_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808","volume":"34","author":"B Lockshin","year":"2021","unstructured":"Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. Dermatol Ther. 2021;34(2): e14808. https:\/\/doi.org\/10.1111\/dth.14808.","journal-title":"Dermatol Ther."},{"issue":"15","key":"843_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"16","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;16(15):1649\u201358. https:\/\/doi.org\/10.2147\/CCID.S364640.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"843_CR9","doi-asserted-by":"publisher","unstructured":"Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022; https:\/\/doi.org\/10.1080\/09546634.2022.2081655","DOI":"10.1080\/09546634.2022.2081655"},{"issue":"12","key":"843_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/PTT.S372262","volume":"14","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;14(12):205\u201312. https:\/\/doi.org\/10.2147\/PTT.S372262.","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"843_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13555-022-00686-1","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Burge R, Gallo G, Charbonneau B, Malatestinic W, Zhu B, Wan F, Lockshin B. A retrospective cohort analysis of treatment patterns over 1\u00a0year in patients with psoriasis treated with ixekizumab or guselkumab. Dermatol Ther (Heidelb). 2022;12(3):701\u201314. https:\/\/doi.org\/10.1007\/s13555-022-00686-1.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"843_CR12","doi-asserted-by":"publisher","unstructured":"Blauvelt A, Shi N, Murage M, Ridenour T, Lew C, Somani N, Zhu B, Zimmerman N, Kern S, Burge R. Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: a real-world study. J Drugs Dermatol. 2022;21(4):399-407. https:\/\/doi.org\/10.36849\/JDD.6336","DOI":"10.36849\/JDD.6336"},{"issue":"7","key":"843_CR13","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1007\/s12325-022-02155-9","volume":"39","author":"C Leonardi","year":"2022","unstructured":"Leonardi C, Zhu B, Malatestinic WN, Eastman WJ, Guo J, Murage MJ, Choong CK, Burge R, Blauvelt A. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan\u00ae\u00a0databases. Adv Ther. 2022;39(7):3214\u201324. https:\/\/doi.org\/10.1007\/s12325-022-02155-9.","journal-title":"Adv Ther."},{"issue":"8","key":"843_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15608","volume":"35","author":"P Malagoli","year":"2022","unstructured":"Malagoli P, Dapavo P, Pavia G, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dini V, Girolomoni G, Guarneri C, Loconsole F, Narcisi A, Sampogna F, Travaglini M, Costanzo A. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis). Dermatol Ther. 2022;35(8): e15608. https:\/\/doi.org\/10.1111\/dth.15608.","journal-title":"Dermatol Ther."},{"key":"843_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-022-00795-x","volume":"5","author":"L Gargiulo","year":"2022","unstructured":"Gargiulo L, Ibba L, Pavia G, Vignoli CA, Piscazzi F, Valenti M, Sanna F, Perugini C, Avagliano J, Costanzo A, Narcisi A. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;5:1\u201316. https:\/\/doi.org\/10.1007\/s13555-022-00795-x.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"843_CR16","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1111\/jdv.18069","volume":"36","author":"G Avallone","year":"2022","unstructured":"Avallone G, Cariti C, Dapavo P, Ortoncelli M, Conforto L, Mastorino L, Roccuzzo G, Cavallo F, Rubatto M, Quaglino P, Ribero S. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022;36(7):e574\u20136. https:\/\/doi.org\/10.1111\/jdv.18069.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"843_CR17","doi-asserted-by":"crossref","unstructured":"Imafuku S, Torisu-Itakura H, Nishikawa A, Zhao F, Cameron GS, Japanese U-SG. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1). J Dermatol. 2017;44(11):1285\u201390.","DOI":"10.1111\/1346-8138.13927"},{"issue":"2","key":"843_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40257-018-0408-z","volume":"20","author":"A McMichael","year":"2019","unstructured":"McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF. Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the pooled AMAGINE-2\/-3 randomized trials. Am J Clin Dermatol. 2019;20(2):267\u201376.","journal-title":"Am J Clin Dermatol"},{"key":"843_CR19","doi-asserted-by":"crossref","unstructured":"Nakagawa H, Niiro H, Ootaki K, Japanese brodalumab study g. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44\u201352.","DOI":"10.1016\/j.jdermsci.2015.10.009"},{"issue":"3","key":"843_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et\u00a0al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"21 Suppl","key":"843_CR21","first-page":"S403","volume":"23","author":"JJ Wu","year":"2017","unstructured":"Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am J Manag Care. 2017;23(21 Suppl):S403\u201316.","journal-title":"Am J Manag Care"},{"issue":"6","key":"843_CR22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.12773","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et\u00a0al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"843_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et\u00a0al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362.","journal-title":"J Dermatol"},{"issue":"4","key":"843_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et\u00a0al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"key":"843_CR25","doi-asserted-by":"publisher","unstructured":"Zhang D, Qiu J, Liao X, et\u00a0al. Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between whites and Asians: a systematic review and meta-analysis. Front Med 2022;8 (Systematic Review) (In English). https:\/\/doi.org\/10.3389\/fmed.2021.814938.","DOI":"10.3389\/fmed.2021.814938"},{"issue":"2","key":"843_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, et\u00a0al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"843_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","volume":"51","author":"RG Langley","year":"2004","unstructured":"Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician\u2019s global assessment. J Am Acad Dermatol. 2004;51(4):563\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"843_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933\u201343.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"843_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et\u00a0al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"3","key":"843_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"5","key":"843_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"843_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"843_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K-L Liang","year":"1986","unstructured":"Liang K-L, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13\u201322.","journal-title":"Biometrika"},{"issue":"2","key":"843_CR34","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65\u201370.","journal-title":"Scand J Stat"},{"issue":"23","key":"843_CR35","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"issue":"9","key":"843_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel MC. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033\u20139. https:\/\/doi.org\/10.1002\/pds.4297.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"843_CR37","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374. https:\/\/doi.org\/10.1007\/s12325-018-0805-y.","journal-title":"Adv Ther."},{"issue":"3","key":"843_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","volume":"11","author":"AJ Averitt","year":"2020","unstructured":"Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med. 2020;11(3):67. https:\/\/doi.org\/10.1038\/s41746-020-0277-8.","journal-title":"NPJ Digit Med"},{"issue":"13","key":"843_CR39","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et\u00a0al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181\u20139.","journal-title":"N Engl J Med"},{"issue":"10201","key":"843_CR40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et\u00a0al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"8","key":"843_CR41","first-page":"866","volume":"10","author":"SK Shah","year":"2011","unstructured":"Shah SK, Arthur A, Yang YC, Stevens S, Alexis AF. A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol. 2011;10(8):866\u201372.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"843_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1346-8138.14338","volume":"45","author":"S Imafuku","year":"2018","unstructured":"Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S, et\u00a0al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805\u201311.","journal-title":"J Dermatol"},{"issue":"2","key":"843_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/13548506.2016.1220603","volume":"22","author":"Z Kwan","year":"2017","unstructured":"Kwan Z, Bong YB, Tan LL, Lim SX, Yong AS, Ch\u2019ng CC, et\u00a0al. Socioeconomic and sociocultural determinants of psychological distress and quality of life among patients with psoriasis in a selected multi-ethnic Malaysian population. Psychol Health Med. 2017;22(2):184\u201395.","journal-title":"Psychol Health Med"},{"issue":"3","key":"843_CR44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/09546634.2015.1101409","volume":"27","author":"C Jackson","year":"2016","unstructured":"Jackson C, Maibach H. Ethnic and socioeconomic disparities in dermatology. J Dermatolog Treat. 2016;27(3):290\u20131.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"843_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups. Am J Clin Dermatol. 2018;19(3):405\u201323.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"843_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/jid.2011.354","volume":"132","author":"T Nijsten","year":"2012","unstructured":"Nijsten T. Dermatology life quality index: time to move forward. J Invest Dermatol. 2012;132(1):11\u20133.","journal-title":"J Invest Dermatol"},{"key":"843_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12955-016-0419-5","volume":"14","author":"Y Liu","year":"2016","unstructured":"Liu Y, Li T, An J, Zeng W, Xiao S. Rasch analysis holds no brief for the use of the dermatology life quality index (DLQI) in Chinese neurodermatitis patients. Health Qual Life Outcomes. 2016;14:17.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"843_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12955-020-01523-9","volume":"18","author":"MFS Jorge","year":"2020","unstructured":"Jorge MFS, Sousa TD, Pollo CF, Paiva BSR, Ianhez M, Boza JC, et\u00a0al. Dimensionality and psychometric analysis of DLQI in a Brazilian population. Health Qual Life Outcomes. 2020;18(1):268.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"843_CR49","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/bjd.15314","volume":"177","author":"FM Ali","year":"2017","unstructured":"Ali FM, Johns N, Finlay AY, Salek MS, Piguet V. Comparison of the paper-based and electronic versions of the dermatology life quality index: evidence of equivalence. Br J Dermatol. 2017;177(5):1306\u201315.","journal-title":"Br J Dermatol"},{"issue":"5","key":"843_CR50","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/00015550510032832","volume":"85","author":"E Mazzotti","year":"2005","unstructured":"Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the dermatology life quality index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol. 2005;85(5):409\u201313.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"843_CR51","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","volume":"180","author":"RB Warren","year":"2019","unstructured":"Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et\u00a0al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069\u201376.","journal-title":"Br J Dermatol"},{"key":"843_CR52","unstructured":"2016\u20132020 American community survey 5-year narrative profile: race. Washington, DC: U.S. Census Bureau; 2022."},{"key":"843_CR53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","volume":"22","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai TF. HLA-Cw1 and psoriasis. Am J Clin Dermatol. 2021;22:339\u201347. https:\/\/doi.org\/10.1007\/s40257-020-00585-1.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"843_CR54","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1159\/000519321","volume":"238","author":"M Kassir","year":"2022","unstructured":"Kassir M, Abdelmaksoud A, Grabbe S, Goldust M. Dermatology life quality index among different cultures: a neglected bias needs to be addressed. Dermatology. 2022;238(4):811\u20132. https:\/\/doi.org\/10.1159\/000519321.","journal-title":"Dermatology"},{"issue":"1","key":"843_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1475-9276-2-12.PMID:14697098;PMCID:PMC328089","volume":"2","author":"GR Sadler","year":"2003","unstructured":"Sadler GR, Ryujin L, Nguyen T, Oh G, Paik G, Kustin B. Heterogeneity within the Asian American community. Int J Equity Health. 2003;2(1):12. https:\/\/doi.org\/10.1186\/1475-9276-2-12.PMID:14697098;PMCID:PMC328089.","journal-title":"Int J Equity Health"},{"key":"843_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40615-021-01164-8","volume":"17","author":"S Yom","year":"2021","unstructured":"Yom S, Lor M. Advancing health disparities research: the need to include Asian American subgroup populations. J Racial Ethn Health Disparities. 2021;17:1\u201335. https:\/\/doi.org\/10.1007\/s40615-021-01164-8.","journal-title":"J Racial Ethn Health Disparities."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00843-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:31:18Z","timestamp":1673029878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00843-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00843-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}